Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar
Drugmaker Cipla, through subsidiary Invagen Pharmaceuticals, has entered into a partnership with China’s Qilu Pharmaceutical for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda (pembrolizumab) in the U.S. Qilu will be responsible for development, regulatory registration and supply of the product while Cipla USA Inc. will be responsible for the commercialisation of…
Read More “Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar” »